Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
589 participants
OBSERVATIONAL
2021-12-10
2022-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients
NCT02010931
Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia
NCT02003612
Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation
NCT05611216
Efficacy of Intermediate and High Intensity Regimens in Patients With Relapsed Acute Lymphoblastic Leukemia
NCT04699162
Chronic Myeloid Leukemia (CML) Real-Life Database
NCT05963061
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute Myeloid Leukemia
Patients ≥18 years old at diagnosis, with de novo AML diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for AML within the study period.
No interventions assigned to this group
Relapsed/Refractory Acute Lymphoid Leukemia
Patients ≥18 years old at diagnosis, with R/R ALL diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for R/R ALL within the study period.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of relapsed/refractory B-cell ALL or de novo AML diagnosed between 01 January 2015 and 31 December 2019
* At least 1 line of treatment for R/R B-cell ALL or de novo AML within the study period
Exclusion Criteria
* Patients with unreliable data as per investigator's opinion (e.g. excessive missing data or inconsistence data)
* Patients that have participated in any interventional clinical trial for relapsed/refractory B-cell ALL or AML at any moment
* Patients with secondary AML
* Patients with any concomitant primary malignancy
* Patients with acute promyelocytic leukemia (APL)
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Italiano de La Plata
La Plata, Buenos Aires, Argentina
Hospital Universitario Austral
Pilar, Buenos Aires, Argentina
FUNDALEU - Fundacion para combatir la Leucemia
Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina
Hospital Privado Centro Medico de Cordoba S.A.
Córdoba, , Argentina
Sanatorio Allende
Córdoba, , Argentina
Hospital São Rafael
Salvador, Estado de Bahia, Brazil
Fundação Doutor Amaral Carvalho
Jaú, SAO Paulo / Brazil, Brazil
Instituto COI de Pesquisa
Rio de Janeiro, , Brazil
ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira
São Paulo, , Brazil
Hospital Beneficência Portuguesa de São Paulo
São Paulo, , Brazil
Hospital Israelita Albert Einstein
São Paulo, , Brazil
Hospital Guillermo Grant Benavente
Concepción, , Chile
Fundacion Santa Fe de Bogota
Bogotá, , Colombia
Oncomedica SA
Montería, , Colombia
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LOYAL
Identifier Type: OTHER
Identifier Source: secondary_id
X9001302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.